Related Experiment Video
Updated: Jul 9, 2026

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
Published on: June 6, 2025
Persistence on treatment and blood pressure control with different first-line antihypertensive treatments: a
Maria Grazia Prandin1, Arrigo F G Cicero, Maddalena Veronesi
1D. Campanacci Clinical Medicine and Applied Biotechnology Department, Alma Mater Studiorum, University of Bologna, Italy.
Insights
Angiotensin receptor blockers (ARBs) and ACE inhibitors showed higher treatment persistence in hypertensive patients compared to other drug classes. Lercanidipine also improved persistence among calcium channel blockers.
Area of Science:
- Cardiology
- Pharmacology
- Hypertension Management
Background:
- Hypertension treatment adherence is crucial for long-term cardiovascular health.
- Comparing first-line antihypertensive drug classes is essential for optimizing patient outcomes.
Purpose of the Study:
- To evaluate treatment persistence and blood pressure reduction across different first-line antihypertensive drug classes.
- To compare the efficacy of specific agents within drug classes, such as lercanidipine versus other calcium channel blockers.
Main Methods:
- A 24-month follow-up study involving 347 hypertensive patients.
- Random allocation to various first-line antihypertensive treatments.
- Analysis of treatment persistence rates and blood pressure changes.
Main Results:
- Higher persistence was observed with Angiotensin Receptor Blockers (ARBs) (68.5%) and ACE inhibitors (64.5%) compared to CCBs (51.6%), beta-blockers (44.8%), and diuretics (34.4%).
- Lercanidipine demonstrated superior persistence (59.3%) versus other CCBs (46.6%).
- Greater blood pressure reduction was achieved with ARBs (-11.2/-5.8 mmHg), ACE inhibitors (-10.5/-5.1 mmHg), and CCBs (-8.5/-4.6 mmHg) than with beta-blockers (-4.0/-2.3 mmHg) and diuretics (-2.3/-2.1 mmHg).
Conclusions:
- ARBs and ACE inhibitors are associated with superior treatment persistence in hypertension management.
- Lercanidipine offers improved persistence within the CCB class.
- These findings support the use of ARBs and ACE inhibitors for better adherence and blood pressure control in hypertensive patients.
Abstract:
We enrolled 347 hypertensive patients, randomly allocated them to different first-line treatments, and followed-up for 24 months. Persistence on treatment was significantly higher in patients treated with ARBs (68.5%) and ACE inhibitors (64.5%) vs. CCBs (51.6%), beta-blockers (44.8%), and diuretics (34.4%). No ARB, ACE inhibitor, beta-blocker, or diuretic was associated with a greater persistence in therapy as compared with the other molecules used in each therapeutic class. The rate of persistence was significantly higher in patients treated with lercanidipine vs. other CCBs (59.3% vs. 46.6%). Systolic and diastolic BP decreased more in patients treated with ARBs (-11.2/-5.8 mmHg), ACE inhibitors (-10.5/-5.1 mmHg), and CCBs (-8.5/-4.6 mmHg) when compared to beta-blockers (-4.0/-2.3 mmHg) and diuretics (-2.3/-2.1 mmHg).
Related Concept Videos
Hypertension IV: Drug Therapy and Lifestyle Modifications
Hypertension III: Clinical Manifestations and Diagnostic Studies
Hypertension V: Nursing Management
Errors occurring during blood pressure monitoring
Several factors...
Hypertension and Regulation of Blood Pressure
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...